Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates

被引:18
|
作者
Sutton, Thomas L. [1 ]
Johnson, Nathalie [2 ]
Schlitt, Alexander [3 ]
Gardiner, Stuart K. [4 ]
Garreau, Jennifer R. [2 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Surg, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Legacy Canc Inst, Legacy Med Grp Surg Oncol, 1040 NW 22nd Ave,Suite 560, Portland, OR 97227 USA
[3] Pacific Northwest, Coll Osteopath Med, 200 Mullins Dr, Lebanon, OR 97355 USA
[4] Legacy Hlth, Legacy Res Inst, Devers Eye Inst, 1225 NE 2nd Ave, Portland, OR 97232 USA
关键词
Complications; Breast cancer; Time to surgery; Neoadjuvant chemotherapy; ANTINEOPLASTIC AGENTS; IMPACT; CYCLOPHOSPHAMIDE; SURGERY; DOXORUBICIN; ADRIAMYCIN; MASTECTOMY; DOCETAXEL; OUTCOMES; TIME;
D O I
10.1016/j.amjsurg.2020.02.061
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of breast cancer. The time interval from last dose of cytotoxic chemotherapy to surgery (TTS) can vary widely. We aimed to evaluate the effect of TTS on postoperative complications. Methods: A retrospective review for women treated with NAC at our institution between January 2011 through December 2016 was performed. Charts were reviewed for postoperative wound complications, and multivariate analysis was performed. Results: 455 patients were identified. Median TTS was 30 days (range 11-228). On multivariate analysis, TTS of less than 28 days was associated with 70% higher odds of any wound complication (p < 0.05). Increasing age had the strongest association with the presence of any wound complication (p < 0.0001). The majority of complications were treated in the outpatient setting (n = 80, 83%). Conclusion: Following NAC for breast cancer, TTS less than 28 days is a risk factor for postoperative wound complications; however, the majority of complications are minor and treated in the outpatient setting. Additional data are needed to determine optimal TTS for oncologic outcomes. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码:741 / 745
页数:5
相关论文
共 50 条
  • [41] Neoadjuvant chemotherapy for breast cancer
    Von Minckwitz G.
    Der Gynäkologe, 2005, 38 (5): : 398 - 408
  • [42] Neoadjuvant chemotherapy for breast cancer
    Sapunar, F
    Smith, IE
    ANNALS OF MEDICINE, 2000, 32 (01) : 43 - 50
  • [43] LOCOREGIONAL RECURRENCE OF BREAST CANCER IN PATIENTS TREATED WITH BREAST CONSERVATION SURGERY AND RADIOTHERAPY FOLLOWING NEOADJUVANT CHEMOTHERAPY
    Min, Sun Young
    Lee, Seung Ju
    Shin, Kyung Hwan
    Park, In Hae
    Jung, So-Youn
    Lee, Keun Seok
    Ro, Jungsil
    Lee, Seeyoun
    Kim, Seok Won
    Kim, Tae Hyun
    Kang, Han-Sung
    Cho, Kwan Ho
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (05): : E697 - E705
  • [44] PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE IN BREAST CANCER
    Myllys, Maiju
    EXCLI JOURNAL, 2021, 20 : 625 - 627
  • [45] Neoadjuvant chemotherapy in breast cancer
    Estévez L.G.
    Revista de Oncología, 2004, 6 (5): : 314 - 320
  • [46] Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer
    Mitri, Samir
    Roldan-Vasquez, Estefania
    Flores, Rene
    Pardo, Jaime
    Borgonovo, Giulia
    Davis, Roger B.
    James, Ted A.
    CLINICAL BREAST CANCER, 2024, 24 (06) : 527 - 532
  • [47] Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
    Schott, Anne F.
    Hayes, Daniel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1747 - 1749
  • [48] Breast cancer, neoadjuvant chemotherapy and residual disease
    Chavez-MacGregor, Mariana
    Gonzalez-Angulo, Ana Maria
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (07) : 461 - 467
  • [49] Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival
    Sutton, Thomas L.
    Schlitt, Alexander
    Gardiner, Stuart K.
    Johnson, Nathalie
    Garreau, Jennifer R.
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (08) : 1761 - 1769
  • [50] Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
    Waqar Haque
    Vivek Verma
    Sandra Hatch
    V. Suzanne Klimberg
    E. Brian Butler
    Bin S. Teh
    Breast Cancer Research and Treatment, 2018, 170 : 559 - 567